#United States #San Diego #Halozyme #ENHANZE #Elektrofi

Halozyme's Strong Third Quarter Performance and Future Outlook

Halozyme Therapeutics, Inc. (NASDAQ: HALO) showcased impressive financial results for the third quarter of 2025, highlighting a remarkable increase in both royalty and total revenues. The company reported a 52% year-over-year increase in royalty revenue, totaling $236 million, while total revenue surged by 22% to reach $354 million. This growth marks a significant achievement for Halozyme as they continue to build on their successful portfolio of ENHANZE-enabled therapies, including notable products like DARZALEX SC, Phesgo, and VYVGART Hytrulo.

Key financial highlights from the report included a 28% rise in net income, bringing the total to $175 million, while the adjusted EBITDA grew by 35% to $248 million. Furthermore, diluted earnings per share (EPS) also saw considerable growth, increasing 36% to $1.43, solidifying Halozyme's robust financial standing.

In light of these encouraging results, Halozyme has updated its financial guidance for 2025, anticipating total revenue to fall between $1,300 million and $1,375 million. This forecast reflects an expected year-over-year growth between 28% and 35%, driven largely by an increase in royalty revenue which is projected to reach $850 million to $880 million. In addition, the adjusted EBITDA forecast has been raised to $885 million to $935 million, with non-GAAP diluted EPS expected to fall between $6.10 and $6.50.

Dr. Helen Torley, President and CEO of Halozyme, emphasized the company's strong position and the continued success of their ENHANZE technology, stating, "These results demonstrate our commitment to enhancing patient outcomes and transforming drug delivery pathways. The continued approval of new indications and products underscores our innovative approach and versatility in the biopharmaceutical space."

This quarter, Halozyme also announced a notable transition in its leadership with the impending departure of Chief Financial Officer Nicole LaBrosse. LaBrosse will remain in the role until March 30, 2026, or until a successor is appointed. As the company moves toward its next chapter of growth, Dr. Torley expressed gratitude for LaBrosse's contributions over the past four years and a forward-looking optimism for the company’s evolving financial strategies.

In recent developments, one of the most significant announcements was Halozyme's agreement to acquire Elektrofi, Inc. for $750 million, with additional milestone payments contingent on regulatory approvals. Elektrofi specializes in ultra-high concentration microparticle technology which complements Halozyme's drug delivery capabilities, particularly in subcutaneous drug administration. This acquisition is poised to enhance Halozyme’s existing portfolio and potentially lead to revenue contributions starting in 2030.

The company’s commitment to innovation is further demonstrated by its ongoing development of ENHANZE technologies. In September, notable partners received regulatory approvals for ENHANZE-enabled therapies. Argenx's VYVDURA for self-injection in Japan and Janssen's new indication for DARZALEX SC in Europe are prime examples that align with Halozyme’s growth trajectory and mission to improve patient care through optimized drug delivery systems.

On the financial front, cash and cash equivalents totaled $702 million by the end of September 2025, reflecting a solid operational cash generation despite share repurchases totaling approximately $92.3 million in the same quarter. The overall balance sheet remains robust, demonstrating a strong liquidity position as Halozyme continues to adapt to the dynamic biopharmaceutical market.

Halozyme's focus on advancing its drug delivery systems and collaborating with key industry partners illustrates its proactive approach to sustaining growth and innovation in the competitive biopharmaceutical landscape. Overall, the results from the third quarter of 2025 not only highlight the company’s strength but also set an optimistic stage for the future as it aims to deliver sustained value for patients, partners, and shareholders alike.

In conclusion, as Halozyme Therapeutics moves forward, its emphasis on expanding its product offerings, enhancing existing technologies, and pursuing strategic partnerships underlines the company's position as a leader in biopharmaceutical innovation. Stakeholders are encouraged to follow the company’s developments closely, especially as they continue to navigate through significant growth opportunities in the coming years.